ATE260643T1 - System zur verabreichung makromolekularer wirkstoffe auf der basis von membran-mimetischen amphiphilen in aerosolform - Google Patents

System zur verabreichung makromolekularer wirkstoffe auf der basis von membran-mimetischen amphiphilen in aerosolform

Info

Publication number
ATE260643T1
ATE260643T1 AT99962011T AT99962011T ATE260643T1 AT E260643 T1 ATE260643 T1 AT E260643T1 AT 99962011 T AT99962011 T AT 99962011T AT 99962011 T AT99962011 T AT 99962011T AT E260643 T1 ATE260643 T1 AT E260643T1
Authority
AT
Austria
Prior art keywords
amphiphils
administration
active agents
agents based
aerosol form
Prior art date
Application number
AT99962011T
Other languages
English (en)
Inventor
Pankaj Modi
Steven R Webb
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Application granted granted Critical
Publication of ATE260643T1 publication Critical patent/ATE260643T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99962011T 1998-12-21 1999-12-16 System zur verabreichung makromolekularer wirkstoffe auf der basis von membran-mimetischen amphiphilen in aerosolform ATE260643T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11324298P 1998-12-21 1998-12-21
US09/397,701 US6271200B1 (en) 1998-12-21 1999-09-16 Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
PCT/CA1999/001233 WO2000037053A1 (en) 1998-12-21 1999-12-16 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles

Publications (1)

Publication Number Publication Date
ATE260643T1 true ATE260643T1 (de) 2004-03-15

Family

ID=26810842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99962011T ATE260643T1 (de) 1998-12-21 1999-12-16 System zur verabreichung makromolekularer wirkstoffe auf der basis von membran-mimetischen amphiphilen in aerosolform

Country Status (11)

Country Link
US (1) US6271200B1 (de)
EP (1) EP1140020B1 (de)
JP (1) JP2004537493A (de)
AT (1) ATE260643T1 (de)
AU (1) AU1852000A (de)
CA (1) CA2353848A1 (de)
DE (1) DE69915347T2 (de)
DK (1) DK1140020T3 (de)
MX (1) MXPA01006379A (de)
NZ (1) NZ512046A (de)
WO (1) WO2000037053A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6290987B1 (en) * 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6350432B1 (en) * 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
FR2798288B1 (fr) * 1999-09-14 2001-11-30 Capsulis Compositions vaccinales destinees a une administration par voie muqueuse
FR2806913B1 (fr) * 2000-03-31 2003-01-31 Pf Medicament Utilisation d'ammoniums quaternaires aliphatiques comme adjuvant dans une composition pharmaceutique administrable par voie mucosale
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
US7335686B2 (en) * 2003-10-20 2008-02-26 Council Of Scientific And Industrial Research Method and composition for treating osteoporosis
US20100297249A1 (en) * 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
EP2039360A1 (de) * 2007-09-19 2009-03-25 Euro-Celtique S.A. Nicht-invasive Direktverabreichung von Opioiden ins Zentralnervensystem
JP2012526840A (ja) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
JP5892940B2 (ja) 2009-11-25 2016-03-23 アリスジェン ソシエテ アノニム クラウン化合物及び／又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
CN102988294B (zh) * 2012-12-13 2015-03-11 上海纳米技术及应用国家工程研究中心有限公司 一种氟碳化合物脂质体的制备方法
WO2019129761A1 (en) * 2017-12-27 2019-07-04 Ursapharm Arzneimittel Gmbh Compositions and methods for eye and nose care

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4900730A (en) 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
US4708861A (en) 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
JPH0753661B2 (ja) 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
FR2571963B1 (fr) 1984-10-24 1987-07-10 Oreal Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition.
EP0200383A3 (de) 1985-04-15 1987-09-02 Eli Lilly And Company Verfahren zur Verabreichung von Insulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US4839111A (en) 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
US5147723A (en) 1987-07-28 1992-09-15 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5234767A (en) 1987-03-13 1993-08-10 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
CA2033725C (en) 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
US5260065A (en) 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
US5643600A (en) 1991-09-17 1997-07-01 Micro-Pak, Inc. Lipid vesicles containing avocado oil unsaponifiables
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
IL122249A0 (en) 1995-06-07 1998-04-05 Alliance Pharmceutical Corp Fluorocarbon pharmaceutical formulations and their preparation
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation

Also Published As

Publication number Publication date
DE69915347T2 (de) 2005-05-04
EP1140020A1 (de) 2001-10-10
US6271200B1 (en) 2001-08-07
NZ512046A (en) 2002-04-26
CA2353848A1 (en) 2000-06-29
DE69915347D1 (de) 2004-04-08
EP1140020B1 (de) 2004-03-03
MXPA01006379A (es) 2002-04-24
WO2000037053A1 (en) 2000-06-29
JP2004537493A (ja) 2004-12-16
AU1852000A (en) 2000-07-12
DK1140020T3 (da) 2004-07-12

Similar Documents

Publication Publication Date Title
ATE260643T1 (de) System zur verabreichung makromolekularer wirkstoffe auf der basis von membran-mimetischen amphiphilen in aerosolform
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
DE69923181D1 (de) Temperatursensitive liposomale formulierung
DK0774959T3 (da) Liposomalt indgivelsessystem for biologisk aktive midler
AU4711296A (en) Method for loading lipid vesicles
DE69828038D1 (de) Lipidkomplexe von sehr unlöslichen platinkomplexen
WO1998019709A3 (en) Cationic reagents for transfection
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
DE69530368D1 (de) Vinca-alkaloid vesikel mit erhöhter wirksamkeit und tumor-zielausrichtung
BG103552A (bg) Терапевтични средства
AR023055A1 (es) Una formulacion farmaceutica de liposoma mixta con vesiculas multilaminar y un proceso para su preparacion
DK0831779T3 (da) Fremgangsmåde til fremstilling af liposompræparat
ES2078510T3 (es) Dispersion acuosa de vesiculas de fosfolipidos, procedimiento para su fabricacion y su uso.
ATE276742T1 (de) Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung
MXPA97007996A (es) Preparado para el transporte de sustancias activas a traves de barreras.
ATE217532T1 (de) Eine didemnin verbindung enthaltende pharmazeutische formulierung
KR950700725A (ko) 리포솜 조성물(liposome composition)
ES2132625T3 (es) Procedimiento de preparacion de liposomas sin utilizacion de disolvente organico.
CA2326348A1 (en) Liposomal bupivacaine compositions and methods of preparation
ATE115403T1 (de) Aus phospholipiden bestehende darreichungsform für wasserunlösliche wirksubstanzen.
DE59903276D1 (de) Mittel zur tumortherapie auf liposomenbasis, die tamoxifen enthalten
BG103739A (en) Aqueous pharmaceutical composition containing hard soluble active substance in water
DE60006000D1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung
ATE199315T1 (de) Liposomzubereitungen enthaltend hybrid-interferon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties